COVID-19: Tiotropium bromide (Spiriva and Spiriva Respimat)
Tiotropium bromide (Spiriva and Spiriva Respimat) can be used treat chronic obstructive pulmonary disease, also called COPD.
Page updated: 18 May 2020
Prescription endorsement requirement removed
We have amended the criteria in section B of the Pharmaceutical Schedule for funded tiotropium bromide:
- Spiriva (powder for inhalation, 18 mcg per dose)
- Spiriva Respimat (soln for inhalation 2.5 mcg per dose).
We have removed the requirement for COPD diagnosis by spirometry. This comes into effect on 1 June 2020.
We're making these changes to support the health system while New Zealand is responding to COVID-19.
Changes are temporary
We intend change the criteria back to the current status once health services have stabilised to a point where it becomes practical to reinstate them.
Who to contact
If you have any questions about this change, email email@example.com
Last updated: 19 May 2020